BPMC - Blueprint Medicines Corporation

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
77.53
+1.14 (+1.49%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close76.39
Open76.12
Bid0.00 x 0
Ask0.00 x 0
Day's range76.12 - 79.07
52-week range31.38 - 92.00
Volume204,958
Avg. volume496,265
Market cap3.325B
BetaN/A
PE ratio (TTM)N/A
EPS (TTM)-3.45
Earnings date7 Mar 2018 - 12 Mar 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est91.75
Trade prices are not sourced from all markets
  • GlobeNewswire12 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Barrett Business Services, Tech Data, Approach Resources, ICF International, Blueprint Medicines, and Government Properties Income Trust — New Research Emphasizes Economic Growth

    NEW YORK, Jan. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Barrett ...

  • Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
    PR Newswirelast month

    Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock

    CAMBRIDGE, Mass., Dec. 15, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the closing of its previously announced underwritten public offering of 4,259,259 shares of its common stock at a public offering price of $81.00 per share, including the exercise in full by the underwriters of their option to purchase additional shares of common stock. Blueprint Medicines estimates net proceeds from the offering will be approximately $325.5 million, after deducting underwriting discounts and commissions and estimated offering expenses. Goldman Sachs & Co. LLC, Morgan Stanley and Cowen acted as joint book-running managers for the offering.

  • Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
    PR Newswirelast month

    Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

    CAMBRIDGE, Mass., Dec. 12, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the pricing of an underwritten public offering of 3,703,704 shares of its common stock at a public offering price of $81.00 per share, before underwriting discounts and commissions. In addition, Blueprint Medicines has granted the underwriters a 30-day option to purchase up to an additional 555,555 shares of its common stock at the public offering price, less underwriting discounts and commissions. Goldman Sachs & Co. LLC, Morgan Stanley and Cowen are acting as joint book-running managers for the offering.

  • Company News For Dec 12, 2017
    Zackslast month

    Company News For Dec 12, 2017

    Companies in the news are: KMG,ARGX,BPMC,BLUE

  • Biotech Stocks Soar On Trial Data At Hematology Conference
    Investor's Business Dailylast month

    Biotech Stocks Soar On Trial Data At Hematology Conference

    Several biotechnology stocks vaulted into double-digit gains after reporting clinical data on blood-disorder medications.

  • Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
    PR Newswirelast month

    Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

    CAMBRIDGE, Mass., Dec. 11, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has commenced an underwritten public offering of $275,000,000 in shares of its common stock. In addition, Blueprint Medicines expects to grant the underwriters a 30-day option to purchase up to an additional $41,250,000 in shares of its common stock in connection with the public offering. All shares of common stock will be offered by Blueprint Medicines.

  • Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity
    PR Newswirelast month

    Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity

    CAMBRIDGE, Mass., Dec. 10, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new data from its ongoing Phase 1 clinical trial of avapritinib (formerly known as BLU-285), a potent and highly selective KIT and PDGFRα inhibitor in development for patients with advanced systemic mastocytosis (SM). The new data from the dose escalation portion of the Phase 1 trial showed strong clinical activity regardless of advanced SM subtype, prior treatment with midostaurin or the presence of additional mutations.

  • Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
    PR Newswire2 months ago

    Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors

    CAMBRIDGE, Mass., Nov. 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced the addition of George Demetri, M.D., a professor of medicine at Harvard Medical School and physician-scientist faculty member at the Dana-Farber Cancer Institute (DFCI), to its Board of Directors. Dr. Demetri, a world-renowned expert in the clinical translation of innovative treatment strategies for cancer, replaces John Mendelsohn, M.D., who is retiring from the Board.

  • Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFRα Genotypes
    PR Newswire2 months ago

    Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFRα Genotypes

    - Global, Randomized Phase 3 Trial in Third-Line GIST on Track to Initiate in First Half 2018 - - New Cohort in Second-Line GIST Added to Ongoing Phase 1 Trial - CAMBRIDGE, Mass. , Nov. 10, 2017 /PRNewswire/ ...

  • Associated Press3 months ago

    Blueprint Medicines reports 3Q loss

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 96 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

  • Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations
    PR Newswire3 months ago

    Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations

    CAMBRIDGE, Mass., Oct. 10, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations. Dr. Murray will join the executive management team and be responsible for technical development, manufacturing and supply chain operations. Chris has more than two decades of strategic and operational experience in pharmaceutical sciences, and he has successfully led manufacturing operations for multiple product candidates through development, regulatory review and commercial launch," said Jeff Albers, Chief Executive Officer of Blueprint Medicines.

  • Associated Press6 months ago

    Blueprint Medicines reports 2Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 86 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • Associated Press9 months ago

    Blueprint Medicines reports 1Q loss

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 84 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

  • Associated Press10 months ago

    Blueprint Medicines reports 4Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 75 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...